
ASLAN Pharmaceuticals Limited ASLN
Annual report 2020
added 08-19-2023
ASLAN Pharmaceuticals Limited ROA Ratio 2011-2026 | ASLN
Annual ROA Ratio ASLAN Pharmaceuticals Limited
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| - | -100.72 | -201.57 | -79.77 | -79.38 | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -79.38 | -201.57 | -115.36 |
ROA Ratio of other stocks in the Biotechnology industry
| Issuer | ROA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
-20.13 | - | 2.43 % | $ 254 M | ||
|
ARCA biopharma
ABIO
|
-21.14 | - | 1052.0 % | $ 415 M | ||
|
Aeterna Zentaris
AEZS
|
-10.45 | - | 5.93 % | $ 314 M | ||
|
Albireo Pharma
ALBO
|
-11.27 | - | -0.23 % | $ 916 M | ||
|
Aileron Therapeutics
ALRN
|
-101.11 | - | 10.36 % | $ 9.8 M | ||
|
I-Mab
IMAB
|
7.43 | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
3.33 | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
23.87 | - | 2.54 % | $ 160 B | ||
|
Biophytis SA
BPTS
|
-89.6 | - | -13.47 % | $ 169 M | ||
|
Ascendis Pharma A/S
ASND
|
-35.36 | $ 219.68 | 1.92 % | $ 5 B | ||
|
Aptinyx
APTX
|
-97.25 | - | -39.0 % | $ 4.57 M | ||
|
Midatech Pharma plc
MTP
|
-42.28 | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-53.39 | - | -1.52 % | $ 24.7 M | ||
|
Seres Therapeutics
MCRB
|
-31.71 | $ 8.28 | - | $ 1.06 B | ||
|
Amphastar Pharmaceuticals
AMPH
|
6.02 | $ 19.45 | 1.14 % | $ 909 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-27.57 | - | - | $ 26.5 M | ||
|
Ayala Pharmaceuticals
AYLA
|
-489.29 | - | - | $ 7.46 M | ||
|
AgeX Therapeutics
AGE
|
-123.72 | - | -10.17 % | $ 12.2 K | ||
|
Acorda Therapeutics
ACOR
|
-232.99 | - | -24.86 % | $ 820 K | ||
|
Mesoblast Limited
MESO
|
-13.8 | $ 15.44 | 7.82 % | $ 10 B | ||
|
Atreca
BCEL
|
-62.67 | - | -11.76 % | $ 5.79 M | ||
|
Acasti Pharma
ACST
|
-13.29 | - | 4.01 % | $ 150 M | ||
|
BeiGene, Ltd.
BGNE
|
3.5 | - | 0.49 % | $ 251 B | ||
|
bluebird bio
BLUE
|
-34.23 | - | - | $ 546 M | ||
|
Институт стволовых клеток человека
ISKJ
|
4.82 | - | - | - | ||
|
Cara Therapeutics
CARA
|
-94.17 | - | -3.03 % | $ 260 M | ||
|
Adverum Biotechnologies
ADVM
|
-72.8 | - | - | $ 86.2 M | ||
|
Acer Therapeutics
ACER
|
-225.71 | - | 2.71 % | $ 14 M | ||
|
Advaxis
ADXS
|
-289.96 | - | -9.65 % | $ 45.9 M | ||
|
CollPlant Biotechnologies Ltd.
CLGN
|
-88.77 | $ 0.67 | -5.25 % | $ 7.67 M | ||
|
Mirum Pharmaceuticals
MIRM
|
-2.77 | $ 90.39 | 2.86 % | $ 4.54 B | ||
|
Avenue Therapeutics
ATXI
|
-437.72 | - | -52.27 % | $ 4.45 M | ||
|
Autolus Therapeutics plc
AUTL
|
-28.19 | $ 1.34 | 1.52 % | $ 342 M | ||
|
MediciNova
MNOV
|
-26.31 | $ 1.45 | - | $ 71.1 M | ||
|
CytomX Therapeutics
CTMX
|
-11.46 | $ 4.37 | 2.95 % | $ 603 M | ||
|
Cyclacel Pharmaceuticals
CYCC
|
-273.86 | - | -5.98 % | $ 34.1 M | ||
|
ChemoCentryx
CCXI
|
-30.95 | - | - | $ 3.74 B | ||
|
Aytu BioScience
AYTU
|
-10.92 | $ 2.69 | 1.37 % | $ 16.9 M | ||
|
Dynavax Technologies Corporation
DVAX
|
2.77 | - | - | $ 2.02 B | ||
|
BioDelivery Sciences International
BDSI
|
26.14 | - | -4.8 % | $ 255 M | ||
|
Enochian Biosciences
ENOB
|
-2162.69 | - | - | $ 40.5 M | ||
|
Aeglea BioTherapeutics
AGLE
|
-19.95 | - | - | $ 1.01 B | ||
|
CureVac N.V.
CVAC
|
-35.55 | - | - | $ 867 M | ||
|
Merck & Co.
MRK
|
13.34 | $ 117.56 | 1.02 % | $ 294 B | ||
|
Marker Therapeutics
MRKR
|
-63.78 | $ 1.37 | 8.73 % | $ 21 M | ||
|
Moderna
MRNA
|
-22.87 | $ 53.09 | 3.41 % | $ 20.7 B | ||
|
Bellerophon Therapeutics
BLPH
|
-249.92 | - | -74.18 % | $ 955 K | ||
|
Akero Therapeutics
AKRO
|
-30.52 | - | - | $ 3.67 B | ||
|
Arbutus Biopharma Corporation
ABUS
|
-35.41 | $ 4.47 | 3.71 % | $ 856 M | ||
|
Homology Medicines
FIXX
|
48.27 | - | 0.77 % | $ 53.4 M |